pociredir
pociredir: sourced relationships with 1 company · 3 clinical trials tracked.
pociredir evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could pociredir → FULC affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | Phase 1 |
Clinical Trial Registry Records (3)
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of Pociredir in Participants With Sickle Cell Disease (SCD) Who Have Participated in a Pociredir Study
Primary endpoint: Number of participants reporting Treatment Emergent Adverse Events (TEAEs)
A Phase 1, Open-Label Study to Assess Pharmacokinetics After Single Doses of Pociredir in Participants With Sickle Cell Disease
Primary endpoint: Plasma concentration of pociredir under fasted and fed conditions
A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects With Sickle Cell Disease (SCD)
Primary endpoint: Treatment-Emergent Adverse Events
Frequently asked questions
Which companies have sourced relationships with pociredir?
pociredir has dated SEC/FDA relationship records for Fulcrum Therapeutics, Inc..
How many clinical trials involve pociredir?
BioSniper tracks 3 clinical trials involving pociredir.